AIMS: This study was undertaken to determine the effects of a short-term dexamethasone treatment on hepatic sensitivities to insulin and glucagon. METHODS: Eleven healthy subjects were studied during one or several of four protocols. In all protocols, somatostatin was infused continuously to inhibit pancreatic hormone secretion. In protocol 1, basal insulin was infused over 300 min while glucagon was infused at a rate of 0.5 mg/kg(-1)/min(-1)during 180 min, then at a rate of 1.5 ng/kg(-1)/min(-1)during 150 min. In protocol 2, the same experiment was performed after a 2 day treatment with 8 mg/day dexamethasone. In protocol 3, the two-step glucagon infusion was performed during insulin infusion at a rate aimed to reproduce the hyperinsulinemia observed during protocol 2. In protocol 4, continuous basal insulin and low glucagon (0.5 mg/kg(-1)/min(-1)) were infused over 330 min. RESULTS: In protocol 1, plasma glucose rose transiently by 2.0 +/- 0.3 mmol/l when the glucagon rate was increased and glucose production increased by 1.4 +/- 0.5 micromol/kg(-1)/min(-1). In protocol 2, the insulin infusion rate (1.85 +/- 0.36 nmol/kg(-1)/min(-1)) required to maintain glycemia was 3.3-fold higher than during protocol 1. Glucagon-induced stimulation of glycemia (by 1.47 +/- 0.5 mmol/l) and endogenous glucose production (by 0.8 +/- 0.3 micromol/kg(-1)/min(-1)) were blunted, but not abolished. In protocol 3, endogenous glucose production was suppressed by 75% by hyperinsulinemia and was not stimulated when the glucagon infusion rate was increased. In protocol 4, endogenous glucose production did not change significantly with time. CONCLUSION: These results indicate that high dose glucocorticoids induce a marked hepatic insulin resistance. Stimulation of glucose production by hyperglucagonemia was maintained in spite of hyperinsulinemia which can be attributed to either hepatic insulin resistance and/or increased hepatic glucagon sensitivity. Copyright 2000 Harcourt Publishers Ltd.
AIMS: This study was undertaken to determine the effects of a short-term dexamethasone treatment on hepatic sensitivities to insulin and glucagon. METHODS: Eleven healthy subjects were studied during one or several of four protocols. In all protocols, somatostatin was infused continuously to inhibit pancreatic hormone secretion. In protocol 1, basal insulin was infused over 300 min while glucagon was infused at a rate of 0.5 mg/kg(-1)/min(-1)during 180 min, then at a rate of 1.5 ng/kg(-1)/min(-1)during 150 min. In protocol 2, the same experiment was performed after a 2 day treatment with 8 mg/day dexamethasone. In protocol 3, the two-step glucagon infusion was performed during insulin infusion at a rate aimed to reproduce the hyperinsulinemia observed during protocol 2. In protocol 4, continuous basal insulin and low glucagon (0.5 mg/kg(-1)/min(-1)) were infused over 330 min. RESULTS: In protocol 1, plasma glucose rose transiently by 2.0 +/- 0.3 mmol/l when the glucagon rate was increased and glucose production increased by 1.4 +/- 0.5 micromol/kg(-1)/min(-1). In protocol 2, the insulin infusion rate (1.85 +/- 0.36 nmol/kg(-1)/min(-1)) required to maintain glycemia was 3.3-fold higher than during protocol 1. Glucagon-induced stimulation of glycemia (by 1.47 +/- 0.5 mmol/l) and endogenous glucose production (by 0.8 +/- 0.3 micromol/kg(-1)/min(-1)) were blunted, but not abolished. In protocol 3, endogenous glucose production was suppressed by 75% by hyperinsulinemia and was not stimulated when the glucagon infusion rate was increased. In protocol 4, endogenous glucose production did not change significantly with time. CONCLUSION: These results indicate that high dose glucocorticoids induce a marked hepatic insulin resistance. Stimulation of glucose production by hyperglucagonemia was maintained in spite of hyperinsulinemia which can be attributed to either hepatic insulin resistance and/or increased hepatic glucagon sensitivity. Copyright 2000 Harcourt Publishers Ltd.
Authors: Silvana M Caparroz-Assef; Ciomar A Bersani-Amado; Ana M Kelmer-Bracht; Adelar Bracht; Emy L Ishii-Iwamoto Journal: Mol Cell Biochem Date: 2007-03-09 Impact factor: 3.396
Authors: Susan J Burke; Heidi M Batdorf; Tai-Yu Huang; Joseph W Jackson; Katarina A Jones; Thomas M Martin; Kristen E Rohli; Michael D Karlstad; Tim E Sparer; David H Burk; Shawn R Campagna; Robert C Noland; Paul L Soto; J Jason Collier Journal: J Steroid Biochem Mol Biol Date: 2019-09-16 Impact factor: 5.011
Authors: Carolyn J Petersons; Brenda L Mangelsdorf; Arthur B Jenkins; Anne Poljak; Malcolm D Smith; Jerry R Greenfield; Campbell H Thompson; Morton G Burt Journal: Diabetes Care Date: 2013-05-13 Impact factor: 19.112
Authors: Alex Rafacho; Luiz M Gonçalves-Neto; Junia C Santos-Silva; Paloma Alonso-Magdalena; Beatriz Merino; Sebastião R Taboga; Everardo M Carneiro; Antonio C Boschero; Angel Nadal; Ivan Quesada Journal: PLoS One Date: 2014-04-04 Impact factor: 3.240
Authors: Laura N Brenner; Josep M Mercader; Catherine C Robertson; Joanne Cole; Ling Chen; Suzanne B R Jacobs; Stephen S Rich; Jose C Florez Journal: J Endocr Soc Date: 2020-08-24